U.K. Drug Risk-Sharing Schemes Eyed Warily By Parliamentary Committee
Executive Summary
Pharmaceutical risk-sharing schemes, in which the government payer and manufacturer split the potential cost of a new or unproven therapy, should be approached cautiously, the U.K. Health Select Committee recommends in a new report